Jubilant Pharmova has announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported ₹76 million in profit from continuing operations for the quarter and ₹149 million for the half-year. Total comprehensive income for the period stood at ₹77 million for the quarter and ₹151 million for the half-year. The results were approved by the Board of Directors on November 13, 2026.
Jubilant Pharmova Announces Q2 FY27 Financial Results
Jubilant Pharmova Limited has disclosed its unaudited financial results for the quarter and half-year ended September 30, 2026. The announcement, made on November 13, 2026, outlines key financial performance indicators following the Board of Directors’ approval.
Standalone Financial Highlights
For the quarter ended September 30, 2026, the company reported a profit of ₹76 million from continuing operations. The profit for the half-year ended September 30, 2026, from continuing operations was ₹149 million. Total comprehensive income for the quarter stood at ₹77 million, and for the half-year, it was ₹151 million.
The standalone statement also shows earnings per share (EPS) of ₹0.48 for the quarter and ₹0.94 for the half-year on a diluted basis.
Consolidated Financial Highlights
On a consolidated basis, Jubilant Pharmova reported a profit attributable to owners of the Company of ₹312 million for the quarter and ₹877 million for the half-year ended September 30, 2026. Total comprehensive income attributable to owners of the Company was ₹1,008 million for the quarter and ₹1,382 million for the half-year.
Consolidated earnings per share (EPS) for the quarter were ₹1.97 basic and ₹1.96 diluted. For the half-year, consolidated EPS was ₹5.54 basic and ₹5.52 diluted.
Other Information
The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and comply with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results have undergone a limited review by the statutory auditors.
Source: BSE
